Eris Lifesciences Share Price in Focus; Q2 FY27 Net Profit Rises 39.2%

Eris Lifesciences reported a net profit of ₹187 crore for the July-September quarter of FY27, against ₹134 crore in the same period last year. Revenue from operations rose to ₹892 crore from ₹792 crore, according to exchange filings dated October 26, 2026. 

The results include an exceptional item of ₹36 crore. Excluding this, net profit was ₹158 crore, compared with ₹134 crore in Q2 FY26. 

EBITDA Margin Falls 

The company recorded EBITDA of ₹309 crore during the quarter, up from ₹288 crore a year earlier. Its EBITDA margin, however, fell to 34.7% from 36.4%. 

Gross profit stood at ₹667 crore, compared with ₹590 crore in the year-ago quarter. Other expenses rose to ₹208 crore from ₹164 crore, while employee costs increased from ₹137 crore to ₹149 crore. 

Domestic Formulations Business 

The Domestic Branded Formulations business brought in ₹809 crore in revenue, compared with ₹708 crore in Q2 FY26. Its EBITDA rose to ₹288 crore from ₹266 crore, while the segment's EBITDA margin declined to 35.7% from 37.6%. 

Eris reported growth of 16.5% in this business after excluding the Zorvia deal. The company licensed certain injectable products and part of its acute portfolio to Zorvia Healthcare. It continues to own the brands and receives a 7% royalty. 

First-Half Results 

For April-September FY27, revenue rose to ₹1,766 crore from ₹1,565 crore. EBITDA increased to ₹606 crore from ₹565 crore, while net profit reached ₹330 crore against ₹260 crore in the previous year. 

Capital expenditure during the first half was ₹220 crore. Operating cash flow was equivalent to 105% of EBITDA, and net debt fell by approximately ₹111 crore. 

Read More: Jyoti Structures Share Price Jumps Over 9%; Bags ₹949.35 Crore Orders from Power Grid! 

Eris Lifesciences Share Price Performance  

As of October 26, 2026, 3:20 pm, Eris Lifesciences share price was trading at ₹1,104.50, a 0.82% increase from the previous closing price. 

Conclusion 

Eris Lifesciences reported higher revenue and net profit for Q2 FY27, alongside a decline in its EBITDA margin. The company also recorded growth in its domestic formulations business during the quarter. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.